1. GeneSight Psychotropic Reduces Overall Medication Cost in Patients Treated with Psychiatric Medications Poster presentation at the American Psychiatric Association Annual Meeting;Allen,2014
2. GeneSight Psychotropic Decreases Medication Costs in a Large, Prospective Case–control Project Poster presentation at the Neuroscience Education Institute (NEI) Psychopharmacology Congress;Allen,2014
3. Clinical Validity: Combinatorial Pharmacogenomics Predicts Antidepressant Responses and Healthcare Utilizations Better Than Single Gene Phenotypes;Altar,2015
4. Local Coverage Determination (LCD): MoPath:GENESIGHT® Assay for Refractory Depression (L35437), 2014;Center for Medicare and Medicaid Services,2014
5. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness;Chou;J. Clin. Psychopharmacol.,2000